Enveric Biosciences, Inc. - Common Stock (NQ:ENVB)

1.470 +0.010 (+0.68%)

Delayed Quote Updated: 9:36 AM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Enveric Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

Enveric Biosciences Secures New U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series

September 15, 2026

From Enveric Biosciences

Via Business Wire

Enveric Biosciences to Present at H.C. Wainwright 28th Annual Global Investment Conference

September 01, 2026

From Enveric Biosciences

Via Business Wire

Enveric Biosciences Reports Financial Results and Provides Corporate Update for Second Quarter 2026

August 14, 2026

From Enveric Biosciences

Via Business Wire

Enveric Biosciences Reports New Preclinical Data Supporting the Non-Hallucinogenic Profile of Lead Candidate EB-003

August 05, 2026

From Enveric Biosciences

Via Business Wire

Enveric Biosciences Welcomes Final FDA Guidance for Psychedelic Drug Development

July 28, 2026

From Enveric Biosciences

Via Business Wire

Enveric Biosciences Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit

June 29, 2026

From Enveric Biosciences

Via Business Wire

Enveric Biosciences Announces Participation in 2026 BIO International Convention

June 16, 2026

From Enveric Biosciences

Via Business Wire

Enveric Biosciences to Participate in the UBS 3rd Virtual CNS Day

June 09, 2026

From Enveric Biosciences

Via Business Wire

Enveric Biosciences Initiates Investigational New Drug (IND)-enabling Genotoxicity Studies of Lead Neuroplastogen Candidate EB-003

June 02, 2026

From Enveric Biosciences

Via Business Wire

Enveric Biosciences Reports Positive Preclinical Results from Phototoxicity Analysis for Lead Neuroplastogen Candidate EB-003

May 19, 2026

From Enveric Biosciences

Via Business Wire

Enveric Biosciences Reports Financial Results and Provides Corporate Update for First Quarter 2026

May 15, 2026

From Enveric Biosciences

Via Business Wire

Enveric Biosciences Expands IP Portfolio with New U.S. Patent Issued for Methods of Treating Psychiatric Disorders

May 13, 2026

From Enveric Biosciences

Via Business Wire

Enveric Biosciences Highlights Positive Results for EB-003 in PTSD Preclinical Model

May 05, 2026

From Enveric Biosciences

Via Business Wire

SmallCap Emerge: ENVB, SMX, ANY, ELPW Across High-Growth Sectors

April 24, 2026

Via AB Newswire

Topics Artificial Intelligence Economy

Enveric Biosciences to Participate in a Panel Discussion at Needham’s Virtual Psychedelics Forum

April 21, 2026

From Enveric Biosciences

Via Business Wire

Kartoon Studios (NYSE: TOON) Gaining Momentum Alongside CMND, ENVB, WLDS, ANY – See Why?

April 20, 2026

Via AB Newswire

Topics Intellectual Property

Enveric Biosciences Announces Closing of Up To $13.9 Million Private Placement Priced At-The-Market Under Nasdaq Rules

April 17, 2026

From Enveric Biosciences, Inc.

Via Business Wire

Enveric Biosciences Announces Up To $13.9 Million Private Placement Priced At-The-Market Under Nasdaq Rules

April 16, 2026

From Enveric Biosciences, Inc.

Via Business Wire

Enveric Biosciences Secures New U.S. Patent for Its EVM301 Series of Drug Candidates

March 31, 2026

From Enveric Biosciences

Via Business Wire

Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2025

March 27, 2026

From Enveric Biosciences

Via Business Wire

Enveric Biosciences Announces Registration of Five Trademarks

March 18, 2026

From Enveric Biosciences, Inc.

Via Business Wire

Enveric Biosciences Announces Withdrawal of Petition Against Its Patent

February 25, 2026

From Enveric Biosciences

Via Business Wire

Enveric Biosciences Reports EB-003 BRET Receptor Engagement Assay Data

February 19, 2026

From Enveric Biosciences

Via Business Wire

Enveric Biosciences Expands Collaboration with TOTEC Pharma through Trademark License and Option

January 29, 2026

From Enveric Biosciences

Via Business Wire

Enveric Biosciences Announces Closing of $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

January 28, 2026

From Enveric Biosciences, Inc.

Via Business Wire

Enveric Biosciences Announces $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

January 28, 2026

From Enveric Biosciences, Inc.

Via Business Wire

Enveric Biosciences Announces Patent Issuance

December 29, 2025

From Enveric Biosciences

Via Business Wire

Enveric Biosciences Announces Closing of Exercise of Warrants for $3.1 Million Gross Proceeds

December 12, 2025

From Enveric Biosciences, Inc.

Via Business Wire

Enveric Biosciences Announces Exercise of Warrants for $3.1 Million Gross Proceeds

December 11, 2025

From Enveric Biosciences, Inc

Via Business Wire

Enveric Biosciences Receives Notice of Allowance for EVM301 Series of Drug Candidates

December 09, 2025

From Enveric Biosciences

Via Business Wire

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.